Antithrombotic Management After Infrarenal Endovascular Aneurysm Repair (EVAR)

Aspirin Therapy (Standard Antiplatelet)

• Low‑dose aspirin (75–100 mg daily) should be started as soon as possible (ideally within the first 6 hours) after EVAR and continued indefinitely in the absence of a specific contraindication. American Heart Association / American College of Cardiology recommendation. 1
• The same low‑dose regimen (75–100 mg daily) reduces major cardiovascular events in patients with atherosclerotic vascular disease, including abdominal aortic aneurysm. American Heart Association / American College of Cardiology. 2
• High‑dose aspirin (325 mg) does not provide additional cardiovascular protection and significantly increases bleeding risk; therefore it should be avoided for long‑term therapy. Praxis Medical Insights (only source reporting this finding). 3

Dual Antiplatelet Therapy (DAPT)

• In selected patients (e.g., complex endovascular procedures, high risk of graft thrombosis, or concomitant symptomatic peripheral arterial disease) a short course of DAPT (aspirin + clopidogrel 75 mg) for 1–6 months may be considered, followed by lifelong low‑dose aspirin. Praxis Medical Insights. 3
• The DAPT regimen consists of clopidogrel 75 mg daily together with low‑dose aspirin for the specified 1–6 month period. Praxis Medical Insights. 3

Oral Anticoagulation (When an Independent Indication Exists)

• Atrial fibrillation: initiate oral anticoagulation when CHA₂DS₂‑VASc ≥ 2 (men) or ≥ 3 (women). Journal of the American College of Cardiology. 4
• Mechanical heart valve: oral anticoagulation is required. Stroke. 5
• Left‑ventricular thrombus or concurrent venous thromboembolism: oral anticoagulation is indicated. American Heart Association / American College of Cardiology. 2

Preferred Anticoagulant Strategy

• Direct oral anticoagulants (DOACs) are preferred over warfarin when anticoagulation is needed. Journal of the American College of Cardiology. 4
• If warfarin is used, maintain an INR of 2.0–3.0 and add low‑dose aspirin (75–81 mg daily). American Heart Association / American College of Cardiology and supporting data. 2
• Combining warfarin with aspirin and/or clopidogrel markedly raises bleeding risk and requires close monitoring. American Heart Association / American College of Cardiology. 2

• For triple therapy (warfarin + clopidogrel + aspirin), target INR 2.0–2.5 with aspirin 75–81 mg and clopidogrel 75 mg. Circulation 2008. 6

• Full‑intensity anticoagulation as monotherapy is not recommended for peripheral arterial disease without another indication, because it increases bleeding without reducing major cardiovascular events. Praxis Medical Insights (only source). 3

Decision Algorithm After EVAR

Step 1 – Assess Need for Anticoagulation

• If no indication (AF, mechanical valve, LV thrombus, VTE), proceed to antiplatelet selection. Circulation 2006. 7
• If yes, start a DOAC (preferred) or warfarin (INR 2.0–3.0) plus low‑dose aspirin. American Heart Association / American College of Cardiology and Journal of the American College of Cardiology. [2][4]

Step 2 – Choose Antiplatelet Regimen (when anticoagulation not required)

• Standard: lifelong low‑dose aspirin 75–100 mg daily. American Heart Association / American College of Cardiology and European Heart Journal 2024. [2][8]
• Consider DAPT (aspirin + clopidogrel 75 mg) for 1–6 months in:
  • Complex EVAR with fenestrated branches,
  • High graft‑thrombosis risk, or
  • Concomitant symptomatic peripheral arterial disease. Praxis Medical Insights. 3

Step 3 – Evaluate Bleeding Risk

• Absolute contraindications to aspirin (e.g., documented allergy) → use clopidogrel 75 mg alone. American Heart Association / American College of Cardiology. 2
• High‑risk bleeding factors (active GI ulcer, uncontrolled hemorrhagic diathesis, concomitant anticoagulants, significant renal impairment) favor monotherapy with aspirin rather than DAPT. American Heart Association / American College of Cardiology and Circulation 2006. [2][7]

Monitoring & Follow‑up

• Routine laboratory monitoring is not required for low‑dose aspirin. American Heart Association / American College of Cardiology. 2
• When warfarin is used, check INR every 4 weeks after stabilization. American Heart Association / American College of Cardiology. 2
• Graft surveillance (Doppler ultrasound or CTA) should follow institutional protocol. European Heart Journal 2024. 8

Special Clinical Scenarios

• Post‑EVAR atrial fibrillation: initiate a DOAC (preferred) or warfarin (INR 2.0–3.0) plus low‑dose aspirin 75–81 mg daily. Journal of the American College of Cardiology and American Heart Association / American College of Cardiology. [4][2]
• Prior coronary artery disease:
  
  • >12 months since the acute coronary event → aspirin alone (75–100 mg). Circulation 2016 and Journal of the American College of Cardiology. [9][4]
  • ≤12 months since the acute event → continue DAPT as directed by cardiology. Circulation 2016. 9
• Surgical aortic graft (non‑endovascular): DAPT for at least 1 month post‑surgery, then lifelong aspirin. Praxis Medical Insights for DAPT duration; Circulation 2006 and Circulation 2011 for subsequent aspirin. [3][7]1

Common Pitfalls to Avoid

• Do not use full‑intensity anticoagulation as sole therapy for graft protection without another indication. Praxis Medical Insights. 3
• Do not discontinue aspirin peri‑operatively for subsequent procedures unless contraindicated. Praxis Medical Insights. 3
• Do not prescribe high‑dose aspirin (>100 mg) for long‑term use; it offers no extra benefit and raises bleeding risk. Praxis Medical Insights. 3
• Do not employ enteric‑coated aspirin formulations for loading doses, as delayed absorption may reduce efficacy. Praxis Medical Insights. 3
• Always assess CHA₂DS₂‑VASc score in patients with atrial fibrillation before deciding on anticoagulation strategy. Journal of the American College of Cardiology. 4

Low‑Dose Aspirin Management After Abdominal Aortic Aneurysm (AAA) Repair

Timing and Indication

• The 2022 ACC/AHA Aortic Disease Guidelines give a Class IIb recommendation (Level C‑LD) that low‑dose aspirin (≈81 mg daily) be started within 6 hours after open or endovascular AAA repair and continued indefinitely in patients with concomitant atheroma or penetrating atherosclerotic ulcer, because AAA is considered a coronary‑artery‑disease equivalent with >20 % 10‑year cardiovascular event risk. 10

Dose and Duration

• The optimal maintenance dose for long‑term therapy is 81 mg daily; higher doses do not improve cardiovascular protection and increase bleeding. This recommendation is supported by the 2011 AHA/ACC guideline and later evidence (Class I, Level A). [11][12]
• Indefinite continuation of low‑dose aspirin after AAA repair is advised for all patients without a specific contraindication, as endorsed by both the 2011 and 2022 ACC/AHA guidelines. [11][10]

Contra‑indications and Alternative Antiplatelet Therapy

• Aspirin should be stopped only for active pathological bleeding, documented aspirin allergy or hypersensitivity (supported by the 2011 AHA/ACC guideline), severe gastrointestinal intolerance despite proton‑pump‑inhibitor therapy (JACC 2013), or intracranial hemorrhage/severe bleeding disorder. [11][13]
• When aspirin is contraindicated, clopidogrel 75 mg daily is recommended as an alternative antiplatelet agent (2011 AHA/ACC guideline). [11][14]

Combination with Anticoagulation

• In patients who require anticoagulation for atrial fibrillation, mechanical valve, left‑ventricular thrombus, or venous thromboembolism, low‑dose aspirin 75‑81 mg daily should be added to the anticoagulant regimen (2011 AHA/ACC guideline). 11
• If warfarin is used, the target INR should be 2.0‑3.0 while maintaining aspirin 75‑81 mg daily (2011 AHA/ACC guideline). 11

Evidence of Risks and Controversies

• A Danish National Registry analysis (2022) reported a higher case‑fatality rate in ruptured AAA among aspirin users (66 % vs 57 %; adjusted mortality rate ratio 1.16), although aspirin use was not linked to an increased risk of rupture itself. 10
• Despite isolated reports of potential harm in specific subgroups (e.g., aneurysm sac enlargement after EVAR, female patients with small aneurysms), the overall cardiovascular benefit of low‑dose aspirin in atherosclerotic vascular disease remains well‑established, and guideline recommendations continue to favor its use. This stance is reinforced by both the 2011 and 2022 ACC/AHA guidelines. [11][10]

Cardiovascular Risk Context

• Patients with AAA have >20 % 10‑year risk of major cardiovascular events, justifying the use of low‑dose aspirin as part of secondary prevention for atherosclerotic disease. 10